Amicus Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Amicus Therapeutics

04/11/2022 19:33

* Amicus Therapeutics Inc  FOLD.OQ   FOLD.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
7. 
    * The Philadelphia Pennsylvania-based  company is expected
to
report  a 5.9% increase in revenue to $84.22 million from $79.55
million a year ago, according to the mean estimate from 11
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Amicus Therapeutics
Inc
is for a loss of 19 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $14​, above​ its last closing price
of $10.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    3.2
 Mar. 31 2022  -0.26       -0.25      -0.30     Missed  -17.6
 Dec. 31 2021  -0.15       -0.16      -0.29     Missed  -85.9​
 Sep. 30 2021  -0.17       -0.17      -0.19     Missed  -13
 ​​Jun.        -0.22       -0.21      -0.19     Beat    10.1
 30 2021                                                
 Mar. 31 2021  -0.24       -0.23      -0.25     Missed  -6.4​
 Dec. 31 2020  -0.24       -0.22      -0.27     Missed  -24.4
 Sep. 30 2020  -0.22       -0.22      -0.23     Missed  -5
 This summary was machine generated November 4 at 19:32 GMT.  All
figures in US dollars  unless otherwise stated